{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Source:
NCT02710669: Phase 1/Phase 2 Interventional Terminated Atrial Fibrillation
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Propafenone, (S)- is an enantiomer Propafenone with anti-arrhythmic and beta-adrenoceptor antagonist activities. In humans (S)-Propafenone administration resulted in a significant reduction of systolic blood pressure and the rate pressure product without any significant effects on heart rate, diastolic blood pressure, PR interval, QRS duration, and QT and QTc values. The difference between the effects of (R)- and (S)-propafenone on systolic blood pressure and rate pressure product was significant. The results from the radioligand binding studies indicate that (S)-propafenone exerts beta-blocking activity in the administered dose. This is further supported by a biochemical assay showing (S)-propafenone to be 54 times more potent than the (R)-enantiomer in displacing (S)-(1251)iodocyanopindolol from 3-receptors of sarcolemma-enriched membranes from the guinea pig heart. (R)- and (S)-propafenone exert different beta-blocking actions but equal effects on the sodium channel-dependent antiarrhythmic class 1 activity. Antiarrhythmic class 1 therapy with reduction of beta-blocking side effects may be attained with optically pure (R)-propafenone hydrochloride instead of the currently used racemic mixture.
Status:
Investigational
Source:
NCT04565444: Not Applicable Interventional Completed Ketosis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT01931943: Phase 1 Interventional Unknown status Advanced Breast Cancer
(2013)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Qilu Pharmaceutical has developed selatinib, an orally available dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 receptor (HER-2) for the treatment of cancer. Selatinib participates in phase I of the ongoing clinical trial to evaluate its safety and tolerability, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity in patients with advanced breast cancer.
Status:
Investigational
Source:
NCT02890173: Phase 3 Interventional Completed Essential Hypertension
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02929862: Phase 1/Phase 2 Interventional Completed Cancer
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Elacridar is an oral bioenhancer that targets multiple drug resistance in tumors. Elacridar is a strong and relatively specific inhibitor of P-gp and BCRP, two main efflux transporters. Development of elacridar is assumed to have been discontinued.
Status:
Investigational
Source:
NCT03872427: Phase 2 Interventional Active, not recruiting Advanced Malignant Solid Neoplasm
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01530893: Not Applicable Interventional Completed Cardiovascular Disease Risk Reduction
(2012)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Flavanone is the basic chemical skeleton for the class of compounds known as Flavanoids. Flavonoids are naturally occurring secondary plant metabolites. They are mainly found in cereals and herbs. In the western diet, the estimated daily intake of flavonoids is in the range of 20 -50 mg per day. Flavonoids as a class generally have effects on CYP (P450) activity, and therefore may affect drug metabolisms.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
